Anti-idiotype cancer vaccine 1A7 - Titan

Drug Profile

Anti-idiotype cancer vaccine 1A7 - Titan

Alternative Names: 1A7; anti-Id antibody 1A7; GD2 anti-idiotype cancer vaccine - Titan; TriGem

Latest Information Update: 26 Aug 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Titan Pharmaceuticals
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma; Neuroblastoma

Most Recent Events

  • 26 Aug 2004 Discontinued - Phase-I for Neuroblastoma in USA (unspecified route)
  • 26 Aug 2004 Discontinued - Phase-II for Malignant melanoma in USA (SC)
  • 23 Jul 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top